Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Angew+Chem+Int+Ed+Engl 2021 ; 60 (18): 10266-10272 Nephropedia Template TP
Sun M; Liu S; Wei X; Wan S; Huang M; Song T; Lu Y; Weng X; Lin Z; Chen H; Song Y; Yang C
Angew Chem Int Ed Engl 2021[Apr]; 60 (18): 10266-10272 PMID33561300show ga
The COVID-19 pandemic caused by SARS-CoV-2 is threating global health. Inhibiting interaction of the receptor-binding domain of SARS-CoV-2 S protein (S(RBD) ) and human ACE2 receptor is a promising treatment strategy. However, SARS-CoV-2 neutralizing antibodies are compromised by their risk of antibody-dependent enhancement (ADE) and unfavorably large size for intranasal delivery. To avoid these limitations, we demonstrated an aptamer blocking strategy by engineering aptamers' binding to the region on S(RBD) that directly mediates ACE2 receptor engagement, leading to block SARS-CoV-2 infection. With aptamer selection against S(RBD) and molecular docking, aptamer CoV2-6 was identified and applied to prevent, compete with, and substitute ACE2 from binding to S(RBD) . CoV2-6 was further shortened and engineered as a circular bivalent aptamer CoV2-6C3 (cb-CoV2-6C3) to improve the stability, affinity, and inhibition efficacy. cb-CoV2-6C3 is stable in serum for more than 12 h and can be stored at room temperature for more than 14 days. Furthermore, cb-CoV2-6C3 binds to S(RBD) with high affinity (K(d) =0.13 nM) and blocks authentic SARS-CoV-2 virus with an IC(50) of 0.42 nM.
free
free
free
Angew+Chem+Int+Ed+Engl 2021 ; 60 (18): 10266-10272
